Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs WisdomTree Inc. Common Stock (WT) Price & Performance

Citius Pharmaceuticals IncTrade
WisdomTree Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs WisdomTree Inc. Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while WisdomTree Inc. Common Stock trades at $22.83 (market cap $3.54B). The key difference: WisdomTree Inc. Common Stock is far larger — about 256.7× Citius Pharmaceuticals Inc's market cap, and WisdomTree Inc. Common Stock pays a 0.51% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and WisdomTree Inc. Common Stock for 0 Days on average.

CTXRWT
Market Cap
$13.79M$3.54B
Volume
156,6841,948,608
Sector
HealthFinancials
52-Week High
$1.82$25.04
52-Week Low
$0.48$10.73
Typical Hold Time
16 Days0 Days
Enterprise Value
$3.96M$4.29B
Dividend Yield
—0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.

While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.

WisdomTree Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CTXR
2% Buy98% Sell
Avg holding period · 16 Days
WT
100% Buy0% Sell
Avg holding period · 0 Days

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR →

About WisdomTree Inc. Common Stock

WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.

Read more on WT →